AIM ImmunoTech(us:AIM)

0.1250

+2.21%

Updated on 2025-04-02

Open:0.1232
Close:0.1250
High:0.1347
Low:0.1205
Prev Close:0.1223
Volume:228266.00
Turnover:29252.94
Turnover Ratio:0.32%
Shares:72.29M
MarketCap:9.04M

About

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.
Address:2117 SW Highway 484

Market Movers